esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.
esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.
esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.
Immuno-oncology has been groundbreaking and provided patients with more valuable months of life. However, response rates still remain low at around 25%, and immunotherapy success in relation to age needs further research.
New levels of heat may cause between 9,000 to 40,000 more suicides in the US and Mexico
A 10-year long observational study finds a link between low levels of Vitamin D and an increased incidence of inflammatory diseases of the lung including ILD
With the availability of the new PCSK9 inhibitors Alirocumab and Evolocumab, LDL values can be reduced to below 20 mg/dl for the first time. What is the advantage of such low values? Are patients at risk? A new study provides information.
Human papillomaviruses play an important role in the development of genital warts and the far more dangerous cervical carcinoma. There are well over 140 different HPV types, of which around 40 can infect the anogenital region.
Safety was as expected based on earlier experience with the agent in psoriasis, psoriatic arthritis (PsA), and Crohn’s disease (CD). Based on these results, ustekinumab may have the potential to offer a new treatment option for patients with SLE.
The intestinal immune system must constantly maintain the difficult balance between fighting infections and simultaneously tolerating harmless or useful germs, and our food components.
A recent data analysis of 78 clinical trials of adalimumab demonstrated an overall safety profile consistent with previous findings and the tumor necrosis factor (TNF) inhibitor class.
There are many type 1 diabetes patients who, despite insulin therapy, have poor metabolic control and high HbA1c values. This is often due to increased insulin resistance, which requires high doses of insulin. Could the additional oral administration of metformin be an option?
The largest routine care study of rituximab use in systemic sclerosis (SSc) patients showed significant changes in skin fibrosis but not in lung fibrosis.
The study of mice, published in Nature Communications, led to the discovery that the O-linked N-acetylglucosamine transferase (OGT) molecule sets sex-specific patterns of gene expression.
Apremilast has demonstrated sustained and clinically meaningful improvements in signs and symptoms of psoriatic arthritis, as well as in physical function in patients who continued treatment over 5 years.
A large, ongoing USA study with over 1.5 million cases analyzed lifestyle factors on tumorous cancer risk. The findings hint at how many cancer cases could be prevented with simple lifestyle changes.
Hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis surgery does not improve survival and may increase the rate of complications compared to surgery alone.
New research exposes that the human leukemia virus (HTLV-1) disrupts the regulation processes of thousands of genes and changes intracellular DNA loops, raising the risk of a rare type of leukemia.
A combination therapy with aspirin and low-dose rivaroxaban appears to be more effective in the secondary prevention of cardiovascular events than aspirin monotherapy.
With a modified folfirinox regimen, patients with non-metastatic pancreatic ductal carcinoma in adjuvant chemotherapy achieved a survival of 54.5 months compared to the previous gemcitabine standard of 35 months.
Recent data has shown that once-daily oral 4 mg of baricitinib for patients with systemic lupus erythematosus (SLE) who receive standard background therapy, is associated with significant clinical improvements compared to placebo.
Immunotherapy with the PD1 inhibitor pembrolizumab acts as first-line therapy in patients with advanced NSCLC and PD-L1 expression ≥ 1% better than standard chemotherapy. Patients lived 4 to 8 months longer in the median, with fewer side effects.
The results of a Scottish cluster-randomized study on Type-2 diabetes indicate that the illness could be reversed without anti-diabetic medicines.